UY39007A - Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricas - Google Patents
Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricasInfo
- Publication number
- UY39007A UY39007A UY0001039007A UY39007A UY39007A UY 39007 A UY39007 A UY 39007A UY 0001039007 A UY0001039007 A UY 0001039007A UY 39007 A UY39007 A UY 39007A UY 39007 A UY39007 A UY 39007A
- Authority
- UY
- Uruguay
- Prior art keywords
- dextrometadone
- diseases
- neuropsychiatric disorders
- disease modifying
- modifying treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062956839P | 2020-01-03 | 2020-01-03 | |
| US202062963874P | 2020-01-21 | 2020-01-21 | |
| US202062993188P | 2020-03-23 | 2020-03-23 | |
| US202063010391P | 2020-04-15 | 2020-04-15 | |
| US202063031785P | 2020-05-29 | 2020-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39007A true UY39007A (es) | 2021-07-30 |
Family
ID=76687448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039007A UY39007A (es) | 2020-01-03 | 2021-01-05 | Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230017786A1 (https=) |
| EP (1) | EP4085044A4 (https=) |
| JP (2) | JP2023509484A (https=) |
| KR (1) | KR20220164470A (https=) |
| CN (1) | CN115397804A (https=) |
| AU (1) | AU2020419181A1 (https=) |
| BR (1) | BR112022013160A2 (https=) |
| CA (1) | CA3166254A1 (https=) |
| MX (1) | MX2022007768A (https=) |
| TW (1) | TW202140415A (https=) |
| UY (1) | UY39007A (https=) |
| WO (1) | WO2021138443A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119202724B (zh) * | 2024-09-25 | 2025-05-30 | 宁夏医科大学总医院 | 一种脓毒症心肌病诊断模型的构建方法及诊断系统 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1715843A1 (en) * | 2004-01-29 | 2006-11-02 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions |
| US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
| US9468611B2 (en) * | 2012-09-27 | 2016-10-18 | Relmada Therapeutics, Inc. | d-Methadone for the treatment of psychiatric symptoms |
| EP2906202A4 (en) * | 2012-10-15 | 2016-04-27 | Isa Odidi | ORAL DRUG RELIEF FORMULATIONS |
| AU2018215056A1 (en) * | 2017-01-31 | 2019-08-08 | Charles E. Inturrisi | D-methadone and its derivatives for use in the treatment of disorders of the nervous system |
| CA3064846A1 (en) * | 2017-05-25 | 2018-11-29 | Glytech, Llc | Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders |
| EP3917619A4 (en) * | 2019-01-30 | 2022-10-26 | University of Padova | Structurally modified opioids for prevention and treatment of diseases and conditions |
-
2020
- 2020-12-30 KR KR1020227026586A patent/KR20220164470A/ko active Pending
- 2020-12-30 US US17/787,608 patent/US20230017786A1/en active Pending
- 2020-12-30 JP JP2022541634A patent/JP2023509484A/ja active Pending
- 2020-12-30 WO PCT/US2020/067498 patent/WO2021138443A1/en not_active Ceased
- 2020-12-30 BR BR112022013160A patent/BR112022013160A2/pt unknown
- 2020-12-30 MX MX2022007768A patent/MX2022007768A/es unknown
- 2020-12-30 EP EP20908770.9A patent/EP4085044A4/en active Pending
- 2020-12-30 AU AU2020419181A patent/AU2020419181A1/en active Pending
- 2020-12-30 CA CA3166254A patent/CA3166254A1/en active Pending
- 2020-12-30 CN CN202080097944.9A patent/CN115397804A/zh active Pending
-
2021
- 2021-01-04 TW TW110100157A patent/TW202140415A/zh unknown
- 2021-01-05 UY UY0001039007A patent/UY39007A/es unknown
-
2026
- 2026-01-05 JP JP2026000511A patent/JP2026062924A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023509484A (ja) | 2023-03-08 |
| US20230017786A1 (en) | 2023-01-19 |
| WO2021138443A1 (en) | 2021-07-08 |
| EP4085044A1 (en) | 2022-11-09 |
| MX2022007768A (es) | 2022-09-27 |
| BR112022013160A2 (pt) | 2022-11-08 |
| KR20220164470A (ko) | 2022-12-13 |
| EP4085044A4 (en) | 2024-06-12 |
| CN115397804A (zh) | 2022-11-25 |
| CA3166254A1 (en) | 2021-07-08 |
| JP2026062924A (ja) | 2026-04-10 |
| TW202140415A (zh) | 2021-11-01 |
| AU2020419181A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019005922A2 (es) | Variantes de il-2 para el tratamiento de enfermedades autoinmunes | |
| CL2023000196A1 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| CL2024001022A1 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| MX2020009246A (es) | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| MX2018003331A (es) | Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados. | |
| CL2025002456A1 (es) | Agonistas heterocíclicos de glp-1 | |
| MX380767B (es) | Métodos para reducir el riesgo cardiovascular. | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CO2020016582A2 (es) | Sales de sepiapterina farmacéuticamente aceptables | |
| MX343215B (es) | Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos. | |
| MX387232B (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2018008021A (es) | Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones. | |
| MX2020011740A (es) | Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso. | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| MX2021005751A (es) | Anticuerpos contra mucina 16 y métodos de uso de los mismos. | |
| CO2026004213A2 (es) | Compuestos de piridona y método de preparación de los mismos y aplicación | |
| CO2022005926A2 (es) | Inhibidores del factor d del complemento para administración oral | |
| CL2024002532A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa | |
| UY39007A (es) | Dextrometadona como tratamiento modificador de enfermedad para trastornos y enfermedades neuropsiquiátricas | |
| CL2019002808A1 (es) | Métodos para prevenir o tratar enfermedades oftálmicas. | |
| PY1944026A (es) | Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias | |
| AR106691A1 (es) | Formulaciones oftálmicas de escualamina |